RecruitingNCT06600659

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

A Pilot Study to Establish Incidence and Characteristics of Patients at Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase

Sponsor

Mayo Clinic

Enrollment

10 participants

Start Date

Nov 2, 2023

Study Type

OBSERVATIONAL

Conditions

Hematopoietic and Lymphatic System Neoplasm Acute Lymphobkastic Leukemia

Summary

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Eligibility

Min Age: 1 Year

Plain Language Summary

Simplified for easier understanding

This study is tracking how many patients develop high ammonia levels in the blood — a potential side effect — after receiving a cancer medication called recombinant Erwinia asparaginase, which is used to treat certain blood cancers in children and adolescents. **You may be eligible if...** - You are being treated in a pediatric blood cancer (hematology/oncology) program - You are receiving recombinant Erwinia asparaginase as part of your cancer treatment - You are at least 1 year old **You may NOT be eligible if...** - You are less than 1 year old - You received recombinant Erwinia asparaginase within the past two weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.